US equities
|
MU
$1,084.73
▲+3.75%
SNDK
$1,726.00
▲+3.95%
NVDA
$236.94
▼-0.96%
AMD
$643.13
▼-0.97%
SPCX
$167.69
▼-2.46%
INTC
$113.00
▲+0.45%
TSLA
$376.30
▼-1.15%
AAPL
$335.74
▲+0.63%
MU
$1,084.73
▲+3.75%
SNDK
$1,726.00
▲+3.95%
NVDA
$236.94
▼-0.96%
AMD
$643.13
▼-0.97%
SPCX
$167.69
▼-2.46%
INTC
$113.00
▲+0.45%
TSLA
$376.30
▼-1.15%
AAPL
$335.74
▲+0.63%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Faeth Therapeutics
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
September 01, 2026
From
Faeth Therapeutics
Via
Business Wire
Tickers
FTH
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
August 17, 2026
From
Faeth Therapeutics
Via
Business Wire
Tickers
FTH
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
August 07, 2026
From
Faeth Therapeutics
Via
Business Wire
Tickers
FTH
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
August 04, 2026
From
Faeth Therapeutics
Via
Business Wire
Tickers
FTH
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer
October 27, 2025
From
Faeth Therapeutics
Via
Business Wire
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy
October 19, 2025
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics’ R&D Platform Delivers First Cross-Disease Validation Beyond Oncology
September 30, 2025
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics Announces Late-Breaking Presentation of Positive Phase 2 Data in Ovarian Cancer at ESMO 2025
September 24, 2025
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics Shows Preclinical Proof-of-Concept for Drug-Diet Combination to Treat Cancer, in Peer-Reviewed Publication
May 13, 2025
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer
March 12, 2025
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics Appoints Dr. Stephen Hahn and Dr. Jayson Dallas to Board of Directors
November 22, 2024
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics to Present at Raymond James Biotech Private Company Showcase
July 17, 2024
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics to Participate in Upcoming Jefferies Investor Conference
May 30, 2024
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics to Participate in the Stifel 2023 Healthcare Conference
November 08, 2023
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics Announces National Academy of Medicine Recognition for Co-founder Dr. Siddhartha Mukherjee
October 13, 2023
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer
September 29, 2023
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics Expands Leadership Team with Thomas Strack as Chief Medical Officer and Virginia Casadas as Head of Clinical Operations
April 11, 2022
From
Faeth Therapeutics
Via
Business Wire
Faeth Therapeutics Raises $20M to Advance Precision Nutrition Platform as A New Modality in Cancer Treatment
January 18, 2022
From
Faeth Therapeutics
Via
Business Wire
